Clin Mol Hepatol.
2017 Dec;23(4):273-279. 10.3350/cmh.2017.0108.
Treatment options after sorafenib failure in patients with hepatocellular carcinoma
- Affiliations
-
- 1Memorial Sloan Kettering Cancer Center, New York, NY, USA. abou-alg@mskcc.org
- 2Weill Cornell Medical College, New York, NY, USA.
- KMID: 2406033
- DOI: http://doi.org/10.3350/cmh.2017.0108
Abstract
- Second line therapy after failure of sorafenib continues to be under study. Prognosis of hepatocellular carcinoma is measured in months, with median overall survival reaching 10.7 months with sorafenib. Because of the modest net benefit sorafenib has contributed, and rising incidence of hepatocellular carcinoma in the world, continued efforts are ongoing to look for efficient upfront, second line, or combination therapies. Herein we review the most relevant to date published literature on treatment options beyond sorafenib, reported studies, ongoing investigational efforts, and possibilities for future studies in advanced hepatocellular carcinoma.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure
- Treatments Other than Sorafenib for Patients with Advanced Hepatocellular Carcinoma
- Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma
- Sequential regorafenib or nivolumab therapy in recurrent hepatocellular carcinoma with sorafenib failure in liver transplant patients does not improve prognosis
- The Efficacy of Sorafenib for Patients With Advanced Hepatocellular Carcinoma
